FDA Accepts NDA Submission for Acoramidis in ATTR-CM : vimar

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Related Keywords

, Ahmad Masri , Bridgebio Pharma , Isabelle Lousada , Drug Administration , Amyloidosis Research Consortium , Bio Pharma Incorporated , New Drug Application , Prescription Drug User Fee Act , Amyloidosis Research , Transthyretin Amyloid , Acoramidis Ole Data ,